Introduction Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a significant therapeutic challenge, particularly in patients who are ineligible for transplant or have progressed after standard treatments (1). Emerging therapeutic strategies, such as cereblon E3 ligase modulators (CELMoDs), are being explored to address this u
38 Reached
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Woman presented with Fever of Unknown Origin
7717 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes